Levonorgestrel transdermal - Agile Therapeutics

Drug Profile

Levonorgestrel transdermal - Agile Therapeutics

Alternative Names: AG 890; AG 900; AG-1000; Progestin-only

Latest Information Update: 01 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Agile Therapeutics
  • Class Hormonal replacements; Norpregnanes; Oral contraceptives; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Pregnancy

Most Recent Events

  • 01 Dec 2017 Phase-II clinical trials in Pregnancy (Prevention) in USA (Transdermal) (Agile Therapeutics pipeline, December 2017)
  • 14 Jun 2016 Agile Therapeutics has patent protection for Progestin-only patch in USA
  • 15 Mar 2016 Agile Therapeutics has patent protection for AG 890 in Australia, Japan, Russia and New Zealand (Agile Therapeutics, Form 10-K, march 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top